Howard S. Höchster

Rutgers, The State University of New Jersey

Social SciencesBiochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 36 papers. Top paper: “SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers”.

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Journal of Clinical Oncology(2024)10.1200/jco-24-01383

N/A

1.1DataRank · unranked

51 citations

Gentry Teng King, Sarah Colby, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff +17 more

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

PLoS ONE(2022)10.1371/journal.pone.0271066

N/A

1.0DataRank · unranked

30 citations

Reynold A. Panettieri, Steven K. Libutti, Howard S. Höchster, Norman R. Watts, Paul T. Wingfield +20 more

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

Journal of Clinical Oncology(2025)10.1200/jco-24-01710

N/A

0.458DataRank · unranked

9 citations

Katherine A. Guthrie, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman +15 more

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae114

N/A

0.443DataRank · unranked

10 citations

Paul J. Catalano, Michelle Weitz, Edith Mitchell, Deirdre Jill Cohen, Peter J O’Dwyer +9 more

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps260

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps232

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps158

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3618

N/A

0DataRank · unranked

7 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Development of a novel, pan-variant aerosol intervention for COVID-19

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.09.14.459961

N/A

0DataRank · unranked

6 citations

Reynold A. Panettieri, Steven K. Libutti, Howard S. Höchster, Norman R. Watts, Paul T. Wingfield +20 more

Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.419

N/A

0DataRank · unranked

2 citations

Mai T. Duong, Renee B. Chang, Yuqing Xue, Devora Delman, Ignacio Garrido‐Laguna +15 more

Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.10

N/A

0DataRank · unranked

0 citations

Qian Shi, Jeffrey P. Meyers, Zhaohui Jin, Magali Svrcek, Charles S. Fuchs +14 more

Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3588

N/A

0DataRank · unranked

0 citations

Chao Ma, Fang‐Shu Ou, Alan P. Venook, Kimmie Ng, Donna Niedzwiecki +12 more

Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4131

N/A

0DataRank · unranked

0 citations

Mai T. Duong, Robert D. Boutin, Leon Lenchik, Jiyoon Kim, Namita Gandhi +11 more

Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3647

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.lba490

N/A

0DataRank · unranked

99 citations

Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin +15 more

A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.140

N/A

0DataRank · unranked

7 citations

Katherine A. Guthrie, Scott Kopetz, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih +15 more

Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps784

N/A

0DataRank · unranked

1 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby +7 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps258

N/A

0DataRank · unranked

1 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps257

N/A

0DataRank · unranked

0 citations

Junxiao Hu, Patrick J. Blatchford, Todd M. Pitts, Alexis D. Leal, Sunnie S. Kim +7 more

Endoscopic liquid biopsies of gastric fluid in a large patient cohort reveal DNA content as a candidate tumor biomarker in gastric cancer

medRxiv(2023)10.1101/2023.02.14.23285919

N/A

0DataRank · unranked

0 citations

Thais Fernanda Bartelli, Adriane Pelosof, Cláudia Zitron, Adriana Passos Bueno, Luana Batista do Carmo dos Santos +20 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Evolution of Rapid Clonal Dynamics and Non–Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer

JCO Precision Oncology(2024)10.1200/po.23.00260

N/A

0DataRank · unranked

5 citations

Jillian N. Carrick, Stephanie L. Murphy, Om A. Kothari, Husam Al-Hraishami, Atul Kulkarni +15 more

Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04714-z

N/A

0DataRank · unranked

2 citations

Axel Grothey, Darren Sigal, Heinz-Josef Lenz, Howard S. Höchster, Yee Chao +5 more

Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.3530

N/A

0DataRank · unranked

1 citations

Patrick J. Blatchford, Junxiao Hu, Todd M. Pitts, Adrie Van Bokhoven, Hannah R. Robinson +13 more

Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505

Cancer(2025)10.1002/cncr.35759

N/A

0DataRank · unranked

2 citations

Sarah Colby, Davendra Sohal, Katherine A. Guthrie, Lisa A. Kachnic, E. Gabriela Chiorean +6 more

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115694

N/A

0DataRank · unranked

1 citations

Bert H. O’Neil, Sebastian Stintzing, Fang‐Shu Ou, Tyler Zemla, Donna Niedzwiecki +18 more

Impact of expression of metabolic genes on patient (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.4_suppl.224

N/A

0DataRank · unranked

0 citations

Joshua Millstein, Yan Yang, Karam Ashouri, Shivani Soni, Sandra Algaze +12 more

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

JNCI Cancer Spectrum(2020)10.1093/jncics/pkaa024

N/A

0DataRank · unranked

13 citations

Sui Zhang, Alan P. Venook, Fang‐Shu Ou, Donna Niedzwiecki, Heinz‐Josef Lenz +15 more

Endoscopic liquid biopsies of gastric fluid in a large human patient cohort reveal DNA content as a candidate tumor biomarker in gastric cancer

eLife(2025)10.7554/elife.107103

N/A

0DataRank · unranked

0 citations

Thais Fernanda Bartelli, Adriane Pelosof, Cláudia Zitron, Adriana Passos Bueno, Luana Batista do Carmo dos Santos +20 more

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

European Journal of Cancer(2020)10.1016/j.ejca.2020.01.026

N/A

0DataRank · unranked

43 citations

Shannon McDonough, Anthony B. El-Khoueiry, Tanios Bekaii‐Saab, Stacey Stein, Vaibhav Sahai +9 more

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4504

N/A

0DataRank · unranked

115 citations

Mai T. Duong, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam +7 more

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4003

N/A

0DataRank · unranked

3 citations

Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar +15 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789

N/A

0DataRank · unranked

53 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review

Immunotherapy(2021)10.2217/imt-2020-0329

N/A

0DataRank · unranked

16 citations

Howard S. Höchster, David A. August, Darren R. Carpizo, Kristen Spencer, Aaron Ciner

Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy

Journal of Gastrointestinal Oncology(2021)10.21037/jgo-21-503

N/A

0DataRank · unranked

2 citations

Swati Mamidanna, Anupama Chundury, Mutlay Sayan, H. Richard Alexander, David A. August +11 more